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Introduction: DLL3, an atypical Notch ligand, is
expressed in SCLC tumors but is not detectable in
normal adult tissues. Rovalpituzumab tesirine (Rova-T)
is an antibody-drug conjugate containing a DLL3-
targeting antibody tethered to a cytotoxic agent pyrro-
lobenzodiazepine by means of a protease-cleavable
linker. The efficacy and safety of Rova-T compared
with topotecan as second-line therapy in patients with
SCLC expressing high levels of DLL3 (DLL3-high) was
evaluated.
Methods: The TAHOE study was an open-label, two-to-one
randomized, phase 3 study comparing Rova-T with top-
otecan as second-line therapy in DLL3-high advanced or
metastatic SCLC. Rova-T (0.3 mg/kg) was administered
intravenously on day 1 of a 42-day cycle for two cycles, with
two additional cycles available to patients who met
protocol-defined criteria for continued dosing. Topotecan
(1.5 mg/m2) was administered intravenously on days 1 to 5
of a 21-day cycle. The primary end point was overall sur-
vival (OS).
Results: Patients randomized to Rova-T (n ¼ 296) and
topotecan (n ¼ 148) were included in the efficacy ana-
lyses. The median age was 64 years, and 77% had the
extensive disease at initial diagnosis. The median OS (95%
confidence interval) was 6.3 months (5.6–7.3) in the Rova-
T arm and 8.6 months (7.7–10.1) in the topotecan arm
(hazard ratio, 1.46 [95% confidence interval: 1.17–1.82]).
An independent data monitoring committee recommendedthat enrollment be discontinued because of the shorter OS
observed with Rova-T compared with topotecan. Safety
profiles for both drugs were consistent with previous
reports.
Conclusions: Compared with topotecan, which is the cur-
rent standard second-line chemotherapy, Rova-T exhibited
an inferior OS and higher rates of serosal effusions, photo-
sensitivity reaction, and peripheral edema in patients with
SCLC. A considerable unmet therapeutic need remains in
this population.
 2021 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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SCLC represents approximately 15% of all lung can-
cers.1 SCLC arises from epithelial cells with neuroendo-
crine differentiation and is molecularly and clinically
distinct from other lung cancers.2 The Veterans Admin-
istration Lung Study Group stages SCLC as limited or
extensive. The former is defined as a disease limited to
the chest that can be encompassed by a radiation field
and is treated with curative intent using combined mo-
dality chemoradiotherapy, or surgery and chemotherapy.
September 2021 Rova-T in Second-Line DLL3-High SCLC 1549The extensive-stage disease includes all other cases and
accounts for approximately two-thirds of newly diag-
nosed patients. The preferred combination regimens for
first-line treatment of extensive-stage SCLC (ES-SCLC)
include a platinum agent, etoposide, and a programmed
death-ligand 1 (PD-L1) inhibitor followed by mainte-
nance treatment with a PD-L1 inhibitor.3 Although
approximately 60% to 70% of patients respond to the
initial combination of anti–PD-L1 blockade and
platinum-based chemotherapy, most responses are not
durable, and the median overall survival (OS) is only 12
to 13 months.4,5 Options for patients with relapsed or
recurrent SCLC are limited.
The topoisomerase I inhibitor topotecan has global
approvals for patients with SCLC with platinum-sensitive
disease who progressed 60 or more days after comple-
tion of first-line chemotherapy6; however, its activity is
limited, with a median OS of less than 6 months,7-9 and
hematologic toxicity is substantial.10 Therefore, a
considerable unmet need exists for the second-line
treatment of SCLC.
DLL3 is an atypical Notch receptor family ligand that
is expressed on the surface of tumor cells in greater than
80% of SCLC and neuroendocrine carcinoma cases but is
virtually undetectable in normal adult tissue.11 Thus,
DLL3 is a potentially promising target for an antibody-
drug conjugate in SCLC. Furthermore, DLL3 expression
prechemotherapy and postchemotherapy seems to be
consistent over time, suggesting that treatment does not
interfere with DLL3 expression.12
Rovalpituzumab tesirine (Rova-T) is a first-in-class
antibody-drug conjugate composed of a DLL3-targeting
immunoglobulin G1 monoclonal antibody tethered to
pyrrolobenzodiazepine (PBD), a toxic DNA crosslinking
agent, by means of a protease-cleavable linker.11,13 In a
first-in-human phase 1 study, Rova-T exhibited encour-
aging activity in recurrent SCLC, achieving a 31% and
85% confirmed objective response rate (ORR) and clin-
ical benefit rate (CBR), respectively, on the basis of a
central review, with a median OS of 5.8 months, in pa-
tients whose tumors expressed DLL3 in 50% of cells
(on the basis of an anti-DLL3 mouse antibody immuno-
histochemistry [IHC] assay).13 The phase 2 TRINITY
study evaluated Rova-T in patients with DLL3-
expressing SCLC that recurred after 2 or more sys-
temic chemotherapy regimens. In contrast to the obser-
vations from the phase 1 study, Rova-T activity was
modest in TRINITY, with a confirmed ORR of 12.4% (per
central radiographic assessment) and a median OS of 5.6
months in all patients, and a confirmed ORR of 14.3%
and a median OS of 5.7 months in a subset of DLL3-high
patients (defined as 75% of DLL3-positive tumor cells
using a rabbit anti-DLL3 antibody).14 In this study
(TAHOE), we evaluated the efficacy and safety of Rova-Tcompared with topotecan in the second-line setting
among patients with DLL3-high advanced or metastatic
SCLC.
Materials and Methods
Study Design and Patients
The TAHOE study was an open-label, two-is-to-one
randomized, phase 3 study comparing the efficacy and
safety of Rova-T and topotecan in patients at least 18
years old with histologically or cytologically confirmed,
advanced, or metastatic, DLL3-high SCLC with first
disease progression during or after first-line platinum-
based chemotherapy. Patients with a history of central
nervous system (CNS) metastases were required to
have a radiographically confirmed stable or improved
status of active CNS disease before randomization,
assessed at least 2 weeks after completion of definitive
treatment (surgical resection, whole-brain radiation
therapy, or stereotactic radiotherapy) and at least 4
weeks after previous radiographic assessment, off or
on a stable dose of corticosteroids. No radiographic
evidence of progression of definitively treated CNS
disease was to be present at the baseline tumor
assessment.
Additional eligibility criteria included measurable
disease per Response Evaluation Criteria in Solid Tu-
mors version 1.1 (RECIST v1.1), Eastern Cooperative
Oncology Group performance status (PS) of 0 or 1, and
adequate hematological, hepatic, and renal function. The
key exclusion criteria were the following: (1) clinically
substantial pulmonary disease, cardiac or neurologic
disorder; (2) current occurrence or previous history of
grade 2 or higher pleural or pericardial effusions with an
ongoing requirement for pericardiocentesis or thor-
acentesis (given the occurrence of Rova-T–associated
effusions in previous studies); (3) a history of capillary
leak syndrome; (4) known leptomeningeal metastases;
(5) another invasive malignancy in the previous 2 years;
(6) more than 1 previous systemic therapy regimen for
SCLC; (7) lack of adequate washout from previous anti-
cancer therapy; or (8) previous exposure to a PBD- or
indolinobenzodiazepine-based drug, Rova-T, or topo-
isomerase I inhibitor.
The primary end point was OS. The secondary end
points included: (1) progression-free survival (PFS); (2)
ORR; (3) CBR; (4) duration of response (DOR); and (5)
patient-reported outcomes using the physical func-
tioning domain of the European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire Core 15 Palliative Care (EORTC QLQ-C15-
PAL) questionnaire15 (quality of life questionnaire for
palliative care of patients with cancer) after 6 weeks of
treatment (cycle two, d 1 for Rova-T and cycle three, d 1
for topotecan) and after the final visit.
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the 2013 Declaration of Helsinki. All patients provided
informed consent before screening procedures. The
study design was approved by the institutional
review board or ethics committee of participating in-
stitutions. An independent data monitoring committee
(IDMC) periodically reviewed the safety and efficacy
data. The study is registered with ClinicalTrials.gov
(NCT03061812).Procedures
Archived or fresh tumor material for DLL3 testing
was collected after informed consent and before
randomization. Eligibility required high DLL3 expres-
sion, which is defined as 75% tumor cells staining
positive according to an IHC assay performed at a
designated central laboratory using the DLL3 rabbit
antibody Ventana SP347 (Ventana Medical Systems).
Randomization (2:1) to Rova-T or topotecan was per-
formed within 28 days of screening and was stratified
through the following: (1) a previous history of brain
metastases (yes versus no); (2) previous prophylactic
cranial irradiation (PCI) (for patients with no previous
history of brain metastases; yes versus no); (3) sensi-
tivity to first-line platinum-based regimen (objective
response or stable disease after first-line therapy and
progression or recurrence-free interval 90 d versus
progressive disease [PD] as the best response, or <90
d progression or recurrence-free interval); (4) and
lactate dehydrogenase (LDH) level (>upper limit of
normal [ULN] versus ULN) at the screening.
Rova-T was administered intravenously (IV) at a
dose of 0.3 mg/kg on day 1 of a 42-day cycle for two
cycles. Dose interruptions or reductions were
permitted for patients who exhibited treatment-related
toxicities. Dexamethasone was coadministered orally
twice daily at a dose of 8 mg on day 1, day 1, and day
2 of each cycle. Two additional cycles of Rova-T after
disease progression were permitted for patients who
had achieved stable disease or better, tolerated the
initial treatment, did not progress for at least 12 weeks
after the second dose, had not received additional
anticancer therapy, and had not experienced clinically
substantial symptoms related to disease progression or
decline in PS. Topotecan was administered IV over 30
minutes at a dose of 1.5 mg/m2 on days 1 through 5 of
a 21-day cycle. Lower doses of topotecan were
permitted if required per the local label. Treatment was
continued until PD unless earlier discontinuation was
warranted.
Radiographic assessment by computed tomography
or magnetic resonance imaging was performed every 6
weeks for the first 30 weeks and every 9 weeksthereafter until PD or death. Patients discontinuing for
reasons other than PD were followed up every 6 weeks
until PD, initiation of a new anticancer therapy, or death.
Response criteria were assessed by the investigator us-
ing RECIST v1.1. Treatment-emergent adverse events
(TEAEs) were summarized using the Medical Dictionary
for Regulatory Activities, version 19.1 and graded as per
the National Cancer Institute Common Terminology
Criteria for Adverse Events, version 4.Sample Size and Analyses
The target sample size was estimated to be 600 pa-
tients to reach approximately 489 deaths needed to
detect a 25% reduction in the risk of death (corre-
sponding to a hazard ratio [HR] of 0.75) with Rova-T
versus topotecan at a one-sided significance level of
0.025 and a power of 85%. After their fourth safety re-
view on December 4, 2018, the IDMC recommended that
enrollment be discontinued because OS with Rova-T was
shorter than that of topotecan. No new patients were
enrolled after December 4, 2018 per IDMC recommen-
dation; the already enrolled patients deriving treatment
benefits could complete their assigned treatment. The
last visit of the last patient (end-of-treatment visit)
occurred on February 12, 2020, after which the database
was locked. Data are reported as of February 12, 2020,
and the target sample size was not reached. Of the 287
dosed patients at data cutoff, 174 (61%) had received 2
or more doses of Rova-T and completed the regimen, and
113 (39%) had received 1 dose of Rova-T.
Efficacy analyses were performed in all randomized
patients. OS was defined as the time from randomization
to death from any cause. For patients who were alive,
data were censored at the last date they were docu-
mented to be alive. Patients with no postbaseline infor-
mation were censored at the date of randomization plus
1 day. PFS was defined as the time from randomization
to the first occurrence of investigator-assessed disease
progression or death from any cause. DOR was defined
as the time between first response (complete response
[CR] or partial response [PR], whichever was recorded
first) to first documented tumor progression (assessed
as per RECIST v1.1) or death owing to any cause,
whichever came first. The median OS, PFS, landmark OS
and PFS rates, and DOR were estimated using the
Kaplan-Meier method. HR was determined using a
stratified Cox proportional hazards model with treat-
ment and stratification factors as covariates. For PFS and
DOR, patients without disease progression or death were
censored at the time of the last radiographic assessment.
ORR included confirmed CR and PR on the basis of
RECIST v1.1, from randomization until disease progres-
sion or death. CBR included CR, PR, and stable disease
711 Screened for enrollment
267 Excluded
148 Randomized to 
topotecan
416 Included in safety analyses
129 Received ≥1 dose
148 Discontinued study
  • 112 Death
  • 18 Study terminated by Sponsor
  • 13 Withdrawal by patient
  • 5 Lost to follow-up
  • 0 Other
296 Discontinued study
  • 259 Death
  • 21 Study terminated by Sponsor
  • 13 Withdrawal by patient
  • 2 Lost to follow-up
  • 1 Other
287 Received ≥1 dose
19 Did not receive 
study drug
444 Included in 
efficacy analyses 9 Did not receive 
study drug
296 Randomized to 
Rova-T
Figure 1. TAHOE CONSORT diagram. Rova-T, rovalpituzumab tesirine.
September 2021 Rova-T in Second-Line DLL3-High SCLC 1551(on the basis of RECIST v1.1) from randomization until
disease progression or death. Patients who did not meet
CR or PR, including those who did not have postbaseline
radiologic assessments, were considered nonresponders.
TEAEs were defined as AEs with onset or increase in
severity after the first dose of study drug but no more
than 70 days after the last dose of study drug.
Patient-reported outcomes were collected using the
EORTC QLQ-C15-PAL and the five-level EQ-5D (EQ-5D-
5L) questionnaires at follow-up visits. The change from
the baseline of the items and domains of the QLQ-C15-
PAL were summarized by treatment arm. The change
from baseline of the EQ-5D-5L utility score and visual
analog scale were also summarized by treatment arm.Results
Baseline Characteristics and Patient Disposition
A total of 711 patients were screened between April
11, 2017 and December 7, 2018, and 444 (62%) meeting
high DLL3 expression and other inclusion criteria were
enrolled and randomized to Rova-T (n ¼ 296) or top-
otecan (n ¼ 148) (Fig. 1). Demographic and baseline
characteristics were balanced between treatment arms
and are summarized in Table 1. The median age was 64
years (range: 32–85), 277 patients (62%) were men, and
265 patients (64%) had an Eastern Cooperative
Oncology Group PS of 1. Most patients (n ¼ 339; 77%)
had extensive disease at diagnosis.
As of data cutoff in February 12, 2020, the median
time on Rova-T was 12 weeks (range: 6–108), and the
median number of cycles completed was 2 (1–4). A total
of 178 patients (60%) discontinued Rova-T owing to
the following primary reasons: (1) PD per RECIST v1.1
(n ¼ 95; 32%); (2) AEs not related to diseaseprogression (n ¼ 38; 13%); (3) patient withdrawal (n ¼
12; 4%); (4) study termination by sponsor (n ¼ 3; 1%);
and (5) other reasons (n ¼ 30; 10%). Eighteen patients
(6%) had a dose reduction of Rova-T, with the reasons
for dose reduction being AEs (n ¼ 18; 6%) and other
reasons (n ¼ 1; 0.3%).
The median time on topotecan was 17 weeks (range:
6–79), and the median number of cycles completed was
4 (range: 1–22). A total of 128 patients (86%) dis-
continued topotecan primarily because of the following:
(1) PD per RECIST v1.1 (n ¼ 65; 44%); (2) AEs not
related to disease progression (n ¼ 26; 18%); (3) patient
withdrawal (n ¼ 15; 10%); (4) study terminated by
sponsor (n¼2; 1%); (5) lost to follow-up (n ¼ 1; 1%);
and (6) other reasons (n ¼ 19; 13%). Topotecan dose
reductions occurred in 52 patients (40%), because of
AEs (n ¼ 44; 34%), logistical or scheduling problems
(n ¼ 2; 2%), or other reasons (n ¼ 9; 7%). At cycle one
day 1, 11 patients (9%) received topotecan at 1 mg/m2,
a dose level lower than the protocol-defined level of 1.5
mg/m2.
After data lock (February 12, 2020), all patients dis-
continued from the study. The primary reasons for study
discontinuation in the Rova-T arm were death (n ¼ 259;
88%), termination by sponsor (n ¼ 21; 7%), withdrawal
by patient (n ¼ 13; 4%), lost to follow-up (n ¼ 2; 1%),
and other (n ¼ 1; 0.3%); those in the topotecan arm
were death (n ¼ 112; 76%), termination by sponsor
(n ¼ 18; 12%), withdrawal by patient (n ¼ 13; 9%), and
lost to follow-up (n ¼ 5; 3%).Efficacy
Following the recommendation by the IDMC to dis-
continue study enrollment, the data collection plan was






Median age (range), y 63.0 (36–85) 64.0 (32–85)
Male, n (%) 191 (65) 86 (58)
ECOG PS, n (%)
0 95 (33) 53 (41)
1 191 (67) 74 (57)
2 1 (0.3) 2 (2)
Missing 9 19
VALG stage at initial diagnosis,
n (%)
Extensive disease 224 (76) 115 (78)
Limited disease 69 (24) 32 (22)
Missing 3 1
Response to first-line platinum-
based chemotherapy, n (%)
PD 155 (52) 79 (53)
Objective response or stable
disease
141 (48) 69 (47)
Lactate dehydrogenase, n (%)
>ULN 149 (50) 74 (50)
ULN 147 (50) 74 (50)
History of brain metastases,a n
(%)
Yes 175 (59) 87 (59)
No 121 (41) 61 (41)
Previous PCI,b n (%)
Yes 3 (2) 3 (5)
No 118 (98) 58 (95)
DLL3 expression levelc
0 to <25% 0 0
25% to <75% 0 0
75% 296 (100%) 148 (100%)
CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group;
PCI, prophylactic cranial irradiation; PD, progressive disease; PS, perfor-
mance status; Rova-T, rovalpituzumab tesirine; ULN, upper limit of normal;
VALG, Veterans Administration Lung Study Group.
aPatients with a history of CNS metastases had received definitive treatment
for CNS disease and were required to have no active CNS disease before
randomization.
bPrevious PCI is only conducted in patients without any history of brain
metastases; percentages are calculated out of the number of patients
without any history of brain metastases.
cHigh DLL3 expression is defined as having 75% tumor cells staining positive
using the Ventana DLL3 (SP347) (Ventana Medical Systems) immunohisto-
chemistry assay.
1552 Blackhall et al Journal of Thoracic Oncology Vol. 16 No. 9minimized, and statistical testing for efficacy end points
was not performed as originally planned. For efficacy
end points that did have enough data to implement the
statistical models, results were descriptively summa-
rized by treatment arms.
After a median follow-up of 8.3 months (range: 0.03–
32.1), 262 patients (86%) in the Rova-T arm and 115
patients (78%) in the topotecan arm had died. The me-
dian OS (primary end point) was 6.3 months (95%
confidence interval [CI]: 5.6–7.3) in the Rova-T arm and
8.6 months (95% CI: 7.7–10.1) in the topotecan arm
(HR ¼ 1.46 [95% CI: 1.17–1.82]) (Fig. 2A).Subgroup analysis for OS was also performed on the
basis of various stratification factors (Supplementary
Table 1). Similar to the observations in the overall
population, a significantly shorter median OS in the
Rova-T arm versus the topotecan arm was observed for
patients without brain metastases at baseline, patients
without previous PCI (permitted only in patients without
a history of brain metastases), patients who were re-
fractory or resistant to the first-line platinum-based
regimen, patients with LDH levels greater than ULN, and
patients with extensive disease at initial diagnosis. A
similar trend in the median OS was observed in other
subgroups, although the differences in median OS were
not statistically significant. Notably, in the topotecan
arm, the median OS was substantially longer in patients
with LDH levels less than or equal to ULN (11.6 mo) and
in patients who initially had limited disease (11.0 mo)
versus the corresponding subgroups in the Rova-T arm
(8.9 mo for patients with LDH ULN and 8.5 mo for
patients with limited disease), although these differences
were not statistically significant. Within the Rova-T arm
and within the topotecan arm, the median OS was
numerically longer in patients with LDH less than or
equal to ULN (versus those with LDH >ULN), in patients
with limited disease (versus those with extensive disease
on the basis of the Veterans Administration Lung Study
Group stage at initial diagnosis), and in patients sensitive
to first-line platinum-based chemotherapy (versus those
resistant or refractory to first-line platinum-based ther-
apy). Within the Rova-T arm, the median OS was sub-
stantially longer in patients with a previous history of
brain metastases versus those without a history of brain
metastases (Supplementary Table 1).
The median PFS (by investigator assessment) in the
randomized population was also reduced in the Rova-T
arm (3.0 mo [95% CI: 2.9–3.6]) versus the topotecan
arm (4.3 mo [95% CI: 3.8–5.4]; HR ¼ 1.51 [95% CI:
1.22–1.87]) (Fig. 2B). Among randomized patients with
measurable disease at baseline (n ¼ 416), the ORR was
15% (42 of 287) in the Rova-T arm, and 21% (27 of 129)
in the topotecan arm (Table 2). One CR was observed in
the Rova-T arm and none in the topotecan arm. A total of
41 (14%) had PR in the Rova-T arm compared with 27
patients (21%) in the topotecan arm. The median DOR
was 3.5 months (95% CI: 2.8–4.2) and 4.9 months (95%
CI: 3.9–7.9) in the Rova-T and topotecan arms, respec-
tively. The CBR was 36% (103 of 287) with Rova-T and
43% (56 of 129) with topotecan (Table 2).
Global health and physical functioning per the mean
EORTC QLQ-C15-PAL scores were not appreciably
different between the Rova-T and topotecan arms at
baseline and after 6 weeks of treatment (Table 3). At
week 7, the mean difference in scores between the Rova-
T and topotecan arms was 3.53 (range: 8.23 to 1.16)
6.3 (5.6, 7.3)Rova-T................
8.6 (7.7, 10.1)Topotecan.......
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Figure 2. (A) OS and (B) PFS in all randomized patients. CI, confidence interval; OS, overall survival; PFS, progression-free
survival; Rova-T, rovalpituzumab tesirine.
September 2021 Rova-T in Second-Line DLL3-High SCLC 1553for global health and 0.50 (range: 5.66 to 4.65) for
physical functioning. However, at the final visit (the last
valid postbaseline record of a patient), the mean differ-
ence in scores between the arms of –7.17 (95%
CI: 11.39 to 2.94) for global health and 6.45 (95%
CI: 11.73 to 1.18) for physical functioning suggested
a further decline in global health and physical func-
tioning in the Rova-T arm over time (Table 3).Safety
Patients who received at least one dose of Rova-T
(n ¼ 287) or topotecan (n ¼ 129) were included in
safety analyses. A total of 273 patients (95%) experi-
enced a TEAE in the Rova-T arm, and 125 patients (97%)
experienced a TEAE in the topotecan arm (Table 4). The
most common TEAEs (20%) with Rova-T were pleuraleffusion (29%), decreased appetite (25%), dyspnea
(25%), fatigue (25%), nausea (23%), and pericardial
effusion (20%). In the topotecan arm, anemia (61%),
neutropenia (43%), thrombocytopenia (43%), nausea
(31%), decreased appetite (28%), fatigue (27%), con-
stipation (22%), and leukopenia (20%) were most
common. Grade 3 or higher AEs were observed in 183
patients (64%) in the Rova-T arm and 113 patients
(88%) in the topotecan arm and were primarily hema-
tologic AEs in both arms (Table 4). Serious TEAEs
occurred in 160 patients (56%) in the Rova-T arm and in
74 patients (57%) in the topotecan arm. The most
common serious TEAEs included malignant neoplasm
progression (10%), pneumonia (7%), pleural effusion
(6%), and dyspnea (6%) in the Rova-T arm, and malig-
nant neoplasm progression (13%), febrile neutropenia
(9%), and thrombocytopenia (8%) in the topotecan arm







Objective response,a n (%)
Complete response 1 (0.3) 0 (0)
Partial response 41 (14) 27 (21)
Stable disease 61 (21) 29 (22)
Progressive disease 154 (54) 58 (45)
Not assessable or
incomplete data
30 (10) 15 (12)
Objective response rate,a
n (%)
42/287 (15) 27/129 (21)
Clinical benefit rate,a
n (%)
103/287 (36) 56/129 (43)
Median duration of
response (95% CI),a mo
3.5 (2.8, 4.2) 4.9 (3.9, 7.9)
CI, confidence interval; RECIST, Response Evaluation Criteria in Solid Tumors;
Rova-T, rovalpituzumab tesirine.
aPer investigator assessment on the basis of RECIST version 1.1.
1554 Blackhall et al Journal of Thoracic Oncology Vol. 16 No. 9(Supplementary Table 2). A total of 17% of patients (50
of 287) in the Rova-T arm and 30% (39 of 129) in the
topotecan arm had drug-related serious AEs.
The AEs of special interest (AESI), such as cuta-
neous reaction (39% versus 12%), edema (30% versus
10%), pleural effusion (29% versus 4%), pericardial
effusion (20% versus 2%), and photosensitivity reac-
tion (16% versus 0%), were more common in the
Rova-T arm than in the topotecan arm. Hematologic
AESI of thrombocytopenia (19% versus 48%), anemia
(16% versus 62%), neutropenia (10% versus 62%),
and febrile neutropenia (1% versus 12%) were less
common in the Rova-T arm than in the topotecan arm.
A complete summary of AESI is provided in
Supplementary Table 3.
TEAEs led to death in 64 patients (22%) in the
Rova-T arm and 28 patients (22%) in the topotecan
arm. The most common AEs leading to death in
the Rova-T arm were malignant neoplasm progression
(n ¼ 26; 9%), pneumonia (n ¼ 7; 2%), and general
physical health deterioration (n ¼ 6; 2%), and those in
the topotecan arm were malignant neoplasm progres-
sion (n ¼ 17; 13%) and general physical health dete-
rioration (n ¼ 3; 2%). Five patients in the Rova-T arm
had drug-related AEs leading to death, which included
pneumonia (n ¼ 2), pancreatitis (n ¼ 1), atypical
pneumonia (n ¼ 1), and interstitial lung disease
(n ¼ 1). No deaths due to drug-related AEs were re-
ported in the topotecan arm.Discussion
Rova-T targets a novel SCLC biomarker, DLL3. The
TAHOE study enrolled patients with pretreated SCLCwith high expression of DLL3, with the intent to
select patients most likely to benefit from Rova-T.
However, a shorter OS was observed in the Rova-T
arm compared with the topotecan arm. The same
trend of shorter OS in the Rova-T versus topotecan
arm was observed in subsets defined by stratification
factors such as platinum-sensitive versus refractory
or resistant disease at baseline, the presence or
absence of CNS metastases at baseline, a previous PCI
(permitted only in patients without a history of brain
metastases), and extensive versus limited disease at
initial diagnosis. Notably, median OS was numerically
longer within the Rova-T and topotecan arms for
patients with favorable prognostic stratification fac-
tors, such as LDH less than or equal to ULN (versus
LDH > ULN), limited disease (versus extensive dis-
ease), and platinumsensitivity (versus platinum
resistance or refractoriness). Most patients had
extensive disease at diagnosis, which could explain
the high number of patients with brain metastases at
baseline.
In the overall population, PFS was shorter and ORR
was lower with Rova-T versus topotecan. Similarly, DOR
was also shorter in the Rova-T arm compared with the
topotecan arm. The MERU study, another phase 3 trial
evaluating Rova-T as first-line maintenance therapy for
advanced SCLC, although exhibiting longer PFS in the
Rova-T arm versus the placebo arm, found no OS benefit
at a preplanned interim analysis. The MERU trial was
closed in August 2019. As a result, the development of
Rova-T was discontinued on the basis of results from the
TAHOE and MERU studies.16,17
The present results from TAHOE are similar to a
subset analysis of 238 DLL3-high patients in the
TRINITY study, which evaluated Rova-T (0.3 mg/kg
every 6 wk for two cycles) as a third-line or later
therapy in SCLC—the ORR was 14.3%, the median PFS
was 3.8 months, and the median OS was 5.7 months.14
However, the current efficacy results are inferior to
those observed in the initial phase 1 study evaluating
Rova-T in patients with recurrent ES-SCLC, which
exhibited an investigator-assessed ORR of 38% at active
doses of 0.2 mg/kg or 0.4 mg/kg every 3 weeks or 0.3
mg/kg or 0.4 mg/kg every 6 weeks, with a median PFS
of 4.3 months and also a DOR of 4.3 months in DLL3-
high patients.13 It should be noted that the analysis of
the DLL3-high patients in the phase 1 study was
exploratory and retrospective, the overall sample size
and the size of the DLL3-high patient subset were small,
not all enrolled patients had assessable tissue, and a
different IHC assay was used to quantify DLL3 expres-
sion. All these factors may have contributed to the re-
ported higher response rate in the DLL3-high subset of







































































































































































































































































































































































































































































































































































































































































































































































































































































September 2021 Rova-T in Second-Line DLL3-High SCLC 1555the TAHOE study was selected on the basis of a
maximum tolerated dose and recommended phase 2
dose established in the phase 1 study.13 The dose-
limiting toxic effects at higher doses of Rova-T (0.8
mg/kg every 3 wk) observed in the phase 1 study
limited the longer duration of treatment or higher
dosing in the TAHOE study.
The analysis of quality of life using the EORTC
QLQ-C15-PAL and EQ-5D-5L VAS scores indicated a
higher decline in global health and physical func-
tioning over time in the Rova-T arm compared with
the topotecan arm. The safety profile of Rova-T in the
TAHOE study was similar to that reported in other
clinical studies.13,14 Pleural effusions, pericardial
effusions, edema, cutaneous reactions, photosensi-
tivity reaction, and thrombocytopenia were AESI in
the Rova-T arm. It has been postulated that the
unique toxicity profile of Rova-T is because of the
premature lysis of the linker, causing a systemic
release of cytotoxic PBD.18 Alternatively, a free drug
may have a “bystander effect” on surrounding cells
through diffusion out of the target cells or cleavage
before internalization by cathepsin B, which is
released by tumor cells or tumor-associated
macrophages.14,19
An overall deterioration in the quality of life over
time along with the unique toxicity profile associated
with Rova-T, such as serosal effusions, suggest chal-
lenges for the tolerability of Rova-T treatment and
warrant careful consideration of its potential toxicity
in the fragile ES-SCLC population. In addition, top-
otecan exhibited a superior median OS (8.6 mo
versus 6.3 mo) and CBR (43% versus 36%)
compared with Rova-T, which supports the
continued use of topotecan in the second-line ES-
SCLC setting.
Although Rova-T did not improve the standard
of care in second-line treatment of SCLC, it proved
feasible in this study to select patients on the basis
of tissue expression of DLL3 in the attempt to
improve the therapeutic index of this approach.
Other DLL3-targeting agents are being evaluated in
this setting. AMG 757, a bispecific T-cell engager
antibody against DLL3 and CD3, and AMG 119, an
adoptive cellular therapy designed to target DLL3-
expressing cells, are both under evaluation in
phase 1 studies in patients with SCLC.20,21 DLL3 is
also typically expressed in castration-resistant
neuroendocrine prostate cancer,22 gastrointestinal
neuroendocrine carcinomas,23 and small cell
bladder cancer,24 and thus, may be a useful target
in a number of cancers.
Despite recent approvals of PD-L1 and
programmed cell death protein-1 inhibitors in the






Grade 1–2 Grade 3–4 Grade 5 Any-Grade Grade 1–2 Grade 3–4 Grade 5 Any-Grade
Any TEAE 90 (31) 119 (42) 64 (22) 273 (95) 12 (9) 85 (66) 28 (22) 125 (97)
Pleural effusion 70 (24) 12 (4) 0 82 (29) 5 (4) 0 0 5 (4)
Decreased appetite 64 (22) 9 (3) 0 73 (25) 31 (24) 5 (4) 0 36 (28)
Dyspnea 50 (17) 21(7) 1 (0.3) 72 (25) 24 (19) 1 (1) 0 25 (19)
Fatigue 56 (20) 15 (5) 0 71 (25) 27 (21) 8 (6) 0 35 (27)
Nausea 64 (22) 3 (1) 0 67 (23) 40 (31) 0 0 40 (31)
Pericardial effusion 53 (19) 4 (1) 0 57 (20) 3 (2) 0 0 3 (2)
Peripheral edema 50 (17) 2 (1) 0 52 (18) 11 (9) 0 0 11 (9)
Anemia 27 (9) 19 (7) 0 46 (16) 34 (26) 45 (35) 0 79 (61)
Photosensitivity
reaction
41 (14) 5 (2) 0 46 (16) 0 0 0 0
Thrombocytopenia 17 (6) 27 (9) 0 44 (15) 19 (15) 36 (28) 0 55 (43)
Cough 41 (14) 1 (0.3) 0 42 (15) 16 (12) 0 0 16 (12)
Asthenia 34 (12) 3 (1) 1 (0.3) 38 (13) 18 (14) 3 (2) 0 21 (16)
Constipation 33 (12) 4 (1) 0 37 (13) 29 (23) 0 0 29 (23)
Malignant neoplasm
progression
5 (2) 5 (2) 26 (9) 36 (13) 0 1 (1) 17 (13) 18 (14)
Pneumonia 13 (5) 12 (4) 7 (2) 32 (11) 5 (4) 6 (5) 0 11 (9)
omiting 28 (10) 3 (1) 0 31 (11) 17 (13) 1 (1) 0 18 (14)
Back pain 20 (7) 2 (1) 0 22 (8) 10 (8) 3 (2) 0 13 (10)
Diarrhea 21 (7) 1 (0.3) 0 22 (8) 25 (19) 0 — 25 (19)
Headache 20 (7) 1 (0.3) 0 21 (7) 9 (7) 4 (3) 0 13 (10)
Hypokalemia 11 (4) 7 (2) 0 18 (6) 10 (8) 4 (3) 0 14 (11)
Neutropenia 5 (2) 9 (3) 0 14 (5) 7 (5) 49 (38) 0 56 (43)
Epistaxis 9 (3) 0 0 9 (3) 11 (9) 3 (2) 0 14 (11)
Febrile neutropenia 0 4 (1) 0 4 (1) 1 (1) 13 (10) 1 (1) 15 (12)
Leukopenia 0 4 (1) 0 4 (1) 4 (3) 22 (17) 0 26 (20)
Alopecia 3 (1) 0 0 3 (1) 20 (16) 0 0 20 (16)
Rova-T, rovalpituzumab tesirine; TEAE, treatment-emergent adverse event.
1556 Blackhall et al Journal of Thoracic Oncology Vol. 16 No. 9first-4,5 and third-line settings,25-27 no treatment has
substantially improved OS in ES-SCLC since the 1970s.28
The TAHOE study joins several setbacks in second-line
therapy, including the recent phase 3 CheckMate-331
study, in which the programmed cell death protein-1
inhibitor nivolumab failed to improve OS versus top-
otecan or amrubicin.29 Albeit disappointing, improve-
ments in the understanding of SCLC gained in these trials
may contribute to eventual breakthroughs in the treat-
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